Results 191 to 200 of about 202,276 (321)

P1227: COMPREHENSIVE MOLECULAR SUBTYPING OF DIFFUSE LARGE B-CELL LYMPHOMA CELL LINES AND ASSOCIATION WITH TAFASITAMAB ACTIVITY

open access: gold, 2023
Arshi Arora   +11 more
openalex   +1 more source

From Genomic and Epigenomic Maps to Medicines in Adult T‐Cell Leukemia/Lymphoma

open access: yesCancer Science, EarlyView.
ABSTRACT Adult T‐cell leukemia/lymphoma (ATL) is an aggressive and refractory hematologic malignancy that is caused by human T‐cell leukemia virus type‐1 (HTLV‐1) retrovirus. ATL results from a combination of viral latency and the accumulation of abnormalities throughout the genome, epigenome, transcriptome, and signaling pathways.
Kako Suzuki, Makoto Yamagishi
wiley   +1 more source

PB2342: PROGNOSTIC SIGNIFICANCE OF PRETREATMENT NEUTROPHIL/LYMPHOCYTE RATIO, PLATELET/LYMPHOCYTE RATIO AND SYSTEMIC IMMUNE-INFLAMMATION INDEX IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA

open access: gold, 2023
Ons Charef   +7 more
openalex   +1 more source

Impact of Achieving Progression‐Free Survival 24 on Subsequent Overall Survival in Diffuse Large B‐Cell Lymphoma Patients

open access: yesCancer Science, EarlyView.
The OS for patients after achieving PFS24 or PFS60 was not markedly different from that of the age‐, sex‐, and calendar period‐matched Japanese general population (PFS24: standardized mortality ratio [SMR] 1.29, 95% confidence interval [CI] 0.72–2.12, p = 0.39; PFS60: SMR 1.43, 95% CI 0.47–3.33, p = 0.55).
Ayumi Fujimoto   +11 more
wiley   +1 more source

Pheochromocytoma and Diffuse Large B-Cell Lymphoma in the Ipsilateral Adrenal Gland: A Case Report. [PDF]

open access: yesIJU Case Rep
Maekawa K   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy